

# NIH GUIDE

---

---

## For Grants and Contracts

---

### NOTICE OF MAILING CHANGE

Check here if you wish to  
discontinue receiving this  
publication

Check here if your address has  
changed and you wish to con-  
tinue receiving this publication.  
Make corrections below and  
mail this page to:

NIH Guide  
Distribution Center  
National Institutes of Health  
Room B3BE07, Building 31  
Bethesda, Maryland 20892

---

U.S. DEPARTMENT OF HEALTH  
AND HUMAN SERVICES

OFFICIAL BUSINESS  
Penalty for Private Use, \$300

The NIH Guide announces scientific  
initiatives and provides policy and  
administrative information to indi-  
viduals and organizations who need to  
be kept informed of opportunities,  
requirements, and changes in extra-  
mural programs administered by the  
National Institutes of Health.

Third-Class Mail  
Postage & Fees Paid  
PHS/NIH/OD  
Permit No. G-291

NOTICE

REPRODUCIBILITY OF PAGES IN APPLICATION FORM PHS 398 WITH  
ORANGE PRINT.....1  
National Institutes of Health  
Index: NATIONAL INSTITUTES OF HEALTH

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

APPLICATION OF CHELATE CONJUGATED RADIOLABELED MONOCLONAL  
ANTIBODIES SPECIFICALLY TO DIAGNOSTIC IMAGING (RFA).....1  
National Cancer Institute  
Index: CANCER

EPIDEMIOLOGIC STUDIES OF HIV-ASSOCIATED MALIGNANCIES (RFA).....2  
National Cancer Institute  
Index: CANCER

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH CAREER DEVELOPMENT AWARD.....3  
National Institutes of Health  
Index: RESEARCH CAREER DEVELOPMENT AWARDS

ERRATUM

NIH GUIDE FOR GRANTS AND CONTRACTS - INCORRECT NUMBER..... 5

NOTICE

REPRODUCIBILITY OF PAGES IN APPLICATION FORM PHS 398 WITH  
ORANGE PRINT

P.T. 34: K.W. 1014002

National Institutes of Health

In the new edition of the Application for Public Health Service Grant Form PHS 398, revised 9/86, the original form pages are printed using orange ink. Orange print is transparent to optical scanning systems and therefore this color print was chosen because the ability to automatically transfer information into the NIH computer will be important to NIH in the future. It was recently learned, however, that this color is not reproduced by some duplicating machines and especially machines in which the toner is not fresh.

Applicants are reminded of the importance of submitting legible copies of the application. An application may be considered incomplete and returned if the original and all copies are not legible.

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

APPLICATION OF CHELATE CONJUGATED RADIOLABELED MONOCLONAL  
ANTIBODIES SPECIFICALLY TO DIAGNOSTIC IMAGING

RFA AVAILABLE: 87-CA-33

P.T. 34; K.W. 0706030, 0760045, 0785190

National Cancer Institute

Application Receipt Date: December 1, 1987

The Radiation Research Program (RRP), Division of Cancer Treatment (DCT), of the National Cancer Institute (NCI), announces the availability of a Request for Applications (RFA) on the above program. The main objective of this RFA is to support meritorious research for the development and use of chelate conjugated radiolabeled monoclonal antibodies in diagnostic imaging, staging, and monitoring of cancer therapy.

There has been an impressive advancement in the understanding of factors involved in the in vivo targeting of biologically active molecules which bind to specific recognition sites on tissues. Considerable advances have been made in the area of new radiolabeling methodologies that leave the antibodies highly immunoactive. Much needs to be done, however, to optimize radiochemical labeling techniques so that normal biologic activity of the immunoglobulin is retained and that non-specific localization in normal tissues is minimized. There appear to be biologic issues which need to be settled. These probably are most amenable to the development of new quantitative methodologies, either using SPECT or PET for actually estimating the fraction of the dose of labeled antibody which reaches the tumor site in vivo. Such information has important implications, both for improvement of diagnostic imaging capabilities as well as a better understanding of the biology of immunoconjugates of all types.

It is anticipated that approximately four or possibly five scientifically meritorious applications can be funded.

The label available with the 9/86 revision of application 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

Request for copies of the complete RFA should be addressed to:

Dr. Matti Al-Aish, Deputy Chief  
Diagnostic Imaging Research Branch  
Radiation Research Program  
National Cancer Institute  
National Institutes of Health  
Landow Building, Room 8C09  
Bethesda, Maryland 20892  
Telephone: (301) 496-9531

## EPIDEMIOLOGIC STUDIES OF HIV-ASSOCIATED MALIGNANCIES

RFA AVAILABLE: 87-CA-32

P.T. 34; K.W. 0715120, 0785055, 0755030, 0710065, 0745045

National Cancer Institute

Application Receipt Date: December 1, 1987

### INTRODUCTION

The Extramural Programs Branch, Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute (NCI) is inviting grant applications from interested investigators for epidemiologic studies to establish the incidence rates, natural history, and etiology of malignancies in individuals at risk for human immunodeficiency virus (HIV) infection, using pathologic, biologic, virologic and immunogenetic probes. This RFA announcement is for a single competition with a deadline of December 1, 1987 for receipt of applications. Applications should be prepared and submitted in accordance with the aims and requirements described in the complete RFA document and summarized in the following sections.

### RESEARCH GOALS AND SCOPE

The objective of the proposed RFA is to encourage epidemiologic research into the etiology of HIV-associated malignancies. Questions of interest include: whether any epidemiologic risk factor patterns or laboratory analyses suggest a mechanism of carcinogenesis in contrast to other clinical outcomes of HIV infection; the relationship between the severity and expression of immune alteration in HIV-infected individuals and development and progression of cancer; the effect of host factors such as histocompatibility antigen polymorphisms on susceptibility to HIV-related malignancies; the effect of HIV antigenic variation, and coinfection with related retroviruses or unrelated viruses, on the development of specific malignancies; the relationship of acquired immunodeficiency syndrome (AIDS) prophylaxis and treatments, and related immune alterations, to tumor development and progression; the latency period between exposure to initiating agent(s) and development of malignancy; and the effects of drug and environmental exposures.

Investigations considered responsive to the proposed RFA include, but are not limited to:

- o Epidemiologic studies, in the diverse groups at risk for HIV infection, comparing individuals who develop malignancies to those with other outcomes of HIV infection;
- o Epidemiologic studies comparing individuals with HIV-associated tumors to those with nonepidemic tumors of the same pathologic type, including those occurring in other immunosuppressed states; or
- o Epidemiologic studies of malignancies occurring in individuals receiving treatment for AIDS with particular attention to treatment-related immune alterations.

### MECHANISM OF SUPPORT

The mechanism of support for this RFA will be the traditional National Institutes of Health (NIH) research project grant. Responsibility for the planning, direction and execution of the proposed research will be solely that of the applicant. The total project period for applications submitted in response to the present RFA should not exceed five years. Approximately \$2,000,000 will be set aside in FY88 to fund applications which are submitted in response to this RFA. It is anticipated that at least four or five applications will be funded. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. The earliest feasible start date for the initial awards will be July 1, 1988. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is contingent upon the availability of funds for this purpose. Non-profit and for-profit institutions are eligible to apply. Foreign as well as domestic institutions are eligible. The present RFA announcement is for a single competition with a deadline of December 1, 1987 for receipt of applications. PHS grant policies governing regular research project grants apply to applications received in response to this request.

## INQUIRIES

A copy of the complete RFA describing the research goals and scope, the review criteria, and the procedure for applying can be obtained by contacting:

Dr. G. Iris Obrams  
Program Director, AIDS Epidemiology  
Extramural Programs Branch  
Epidemiology and Biostatistics Program  
Division of Cancer Etiology  
National Cancer Institute  
Landow Building, Room 8C16  
Bethesda, Maryland 20892  
Telephone: (301) 496-9600

Applications must be submitted using Form 398 (Rev. 9/86). The RFA label contained in the application kit must be affixed to the bottom of the face page of the original copy of the application. Failure to use this label could result in delayed processing and review of your application.

## ONGOING PROGRAM ANNOUNCEMENTS

### RESEARCH CAREER DEVELOPMENT AWARD

P.T. 34; K.W. 1014002, 0710030

National Institutes of Health

The National Institutes of Health (NIH) announces changes in the guidelines for Research Career Development Awards (RCDA). Applicants are urged to obtain the complete revised guidelines and to discuss their application with the appropriate NIH staff member indicated below, before preparing an application. These new guidelines will go into effect for the receipt date of February 1, 1988.

The purpose of the RCDA is to provide five years of salary support to investigators who have demonstrated outstanding research potential. In order to enable such investigators to develop this potential, the award guarantees them the ability to devote at least 80 percent of their time to research for five years.

The major new provisions are as follows:

#### GUARANTEED TIME FOR RESEARCH:

Individuals who receive an RCDA are to devote essentially full time to research and research-related activities. The sponsoring institution must guarantee as part of the RCDA application that, if an award is made, the applicant will have at least 80 percent of his/her time available for research. This includes direct supervision of research trainees such as pre- and postdoctoral fellows and attendance at meetings and workshops.

Up to 20 percent of the candidate's time may be spent on research-related activities that would enhance the candidate's research career development. These include additional research training, teaching related to the research goals of the candidate, and clinical activities that would allow the candidate to maintain clinical skills and expertise necessary for the conduct of research. During the period of the award the institution is expected to defer administrative and other service duties which do not contribute to the candidate's research career development.

#### ELIGIBILITY:

Candidates must have demonstrated their independence through independent research accomplishments at the time of application. The candidate should normally have five years of postdoctoral research experience, including two years of experience as an independent investigator with independent peer-reviewed grant support. Applicants who do not meet these criteria can qualify if they demonstrate in the application that they have achieved an equivalent level of experience and independence.

Candidates who have achieved tenure or the equivalent, who have a publication record indicating that they are well established in their field, or who have substantial research support that already requires commitment of a major part of their time are ineligible.

Applicants who currently hold a PHS award in the research career program (K series) (e.g. clinical investigator award, physician scientist award) are not eligible to receive an RCDA.

**RESEARCH SUPPORT:**

At the time of award, the applicant will have to demonstrate that he/she has independent research support sufficient for the research proposed in the RCDA application. This support may be from external or from institutional sources. The awarding unit will not make an award unless such research support is available.

**INQUIRIES:**

The components of the National Institutes of Health which make grants and awards have different, and varying, program goals, program initiatives, and resource constraints. These differences frequently result in quite distinct patterns of awards among the Bureaus, Institutes, and Divisions (BIDs). A particularly wide disparity in the abilities of the various BIDs to make RCDAs has recently been evident. Therefore, all potential applicants are strongly urged to contact the appropriate BID staff person, prior to preparing an application, to obtain current information about the BID's situation with regard to RCDAs. Applicants should be aware, however, that the assignment of an application to a particular BID is governed by the NIH referral guidelines.

National Institute of Environmental Health Sciences  
Dr. Edward Gardner  
Building 3, Room 303B  
National Institutes of Health  
P.O. Box 12233  
Research Triangle Park, North Carolina 27709  
Telephone: (919) 541-7724

National Eye Institute  
Dr. Jack A. McLaughlin  
Building 31, Room 6A51  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-5983

National Heart, Lung, and Blood Institute  
Dr. Henry G. Roscoe  
Westwood Building, Room 7A17A  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7225

National Institute of General Medical Sciences  
Dr. Elke Jordan  
Westwood Building, Room 953  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7061

National Cancer Institute  
Dr. Barney C. Lepovetsky, Chief  
Cancer Training Branch  
Blair Building, Room 424  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 427-8898

National Library of Medicine  
Mr. Peter Clepper, Program Officer  
Building 38A, Room 5S-518  
National Institutes of Health  
Bethesda, Maryland 20894  
Telephone: (301) 496-4221

National Institute of Allergy and Infectious Diseases  
Dr. William E. Bennett  
Westwood Building, Room 7A03  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-5030

Division of Research Resources  
Dr. James F. O'Donnell  
Building 31, Room 5B03  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-6023

National Institute of Arthritis and Musculoskeletal and  
Skin Diseases  
Dr. Richard Lymn  
Westwood Building, Room 403  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7495

National Institute of Diabetes and Digestive and  
Kidney Diseases  
Dr. Walter Stolz  
Westwood Building, Room 657  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7277

National Institute of Neurological and Communicative  
Disorders and Stroke  
Mr. Edward M. Donohue  
Federal Building, Room 1016  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-4188

National Institute on Aging  
Dr. Miriam C. Kelty  
Building 31, Room 5C05  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-9322

National Institute of Child Health and Human Development  
Ms. Hildegard Topper  
Building 31, Room 2A04  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-1848

National Institute of Dental Research  
Dr. Thomas Valega  
Westwood Building, Room 510  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone (301) 496-6324

Application forms and complete RCDA guidelines may be  
obtained from:

Office of Grants Inquiries  
Westwood Building, Room 449  
Division of Research Grants  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7441

#### ERRATUM

The NIH Guide for Grants and Contracts dated July 24, 1987, had an incorrect  
number on the cover page. The correct volume and number follows:

VOL. 16 NO. 25 - JULY 24, 1987